Driven by rapid innovations and the integration of modern technologies, the biotech sector is experiencing robust growth.

The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals' drug to treat acute pain, the health regulator ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), UnitedHealth ...

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading ... changes into account and provides an actionable rating system. The Zacks Rank system, ranging from #1 (Strong Buy) to ...

For example, the Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) share price is up 83% in the last five years, slightly above the market return. Over the last year the stock price is up ...

Below is Validea's guru fundamental report for VERTEX PHARMACEUTICALS INC (VRTX). Of the 22 guru strategies we follow, VRTX rates highest using our P/B Growth Investor model based on the published ...

Investors in Vertex Pharmaceuticals, Inc. (Symbol: VRTX) saw new options begin trading today, for the March 7th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...